Aspiriant LLC Buys Shares of 412 McKesson Co. (NYSE:MCK)

Aspiriant LLC acquired a new stake in shares of McKesson Co. (NYSE:MCK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 412 shares of the company’s stock, valued at approximately $235,000.

A number of other hedge funds have also recently made changes to their positions in MCK. Pure Financial Advisors LLC lifted its stake in shares of McKesson by 3.3% in the 4th quarter. Pure Financial Advisors LLC now owns 792 shares of the company’s stock valued at $452,000 after purchasing an additional 25 shares during the period. Koshinski Asset Management Inc. lifted its stake in shares of McKesson by 0.9% in the fourth quarter. Koshinski Asset Management Inc. now owns 2,404 shares of the company’s stock worth $1,370,000 after buying an additional 22 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in McKesson by 3.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 632 shares of the company’s stock valued at $360,000 after purchasing an additional 22 shares during the last quarter. M.E. Allison & CO. Inc. bought a new position in McKesson during the 4th quarter valued at about $264,000. Finally, Successful Portfolios LLC bought a new stake in McKesson in the 4th quarter worth approximately $219,000. 85.07% of the stock is currently owned by institutional investors.

Insider Activity

In other McKesson news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the sale, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.11% of the company’s stock.

McKesson Stock Performance

Shares of MCK opened at $585.51 on Wednesday. The company has a 50 day moving average price of $594.65 and a 200-day moving average price of $561.08. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $637.51. The stock has a market capitalization of $74.32 billion, a PE ratio of 30.32, a PEG ratio of 1.28 and a beta of 0.52.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping analysts’ consensus estimates of $6.88 by $0.19. The company had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. McKesson’s revenue was up 21.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.23 earnings per share. Equities research analysts forecast that McKesson Co. will post 32.73 EPS for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.49%. The ex-dividend date was Monday, December 2nd. McKesson’s payout ratio is 14.71%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Baird R W upgraded McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Robert W. Baird raised shares of McKesson from a “neutral” rating to an “outperform” rating and raised their target price for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price objective on McKesson from $535.00 to $641.00 and gave the stock an “equal weight” rating in a research note on Friday, December 13th. Citigroup reduced their price objective on McKesson from $713.00 to $677.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Leerink Partners reduced their target price on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.